BIOCYTOGEN
Biocytogen is a clinical stage biopharmaceutical company that integrates proprietary gene editing technology, transgenic mouse platforms to generate fully human antibodies, comprehensive animal models and high-throughput in vivo antibody discovery. We have established fully integrated research and development capabilities ranging from early target discovery to clinical development. Our focus on research and development and technological innovation serves as the cornerstone of our continuing growth. We intend to develop and commercialize first-in-class or best-in-class drugs to contribute to the improvement of human health worldwide.
BIOCYTOGEN
Social Links:
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
2008-11-01
Status:
Active
Contact:
781-587-3558
Email Addresses:
[email protected]
Total Funding:
335.15 M USD
Technology used in webpage:
Domain Not Resolving IPv6 Person Schema Google Google Cloud Cloudflare Hosting Facebook Sharer Gravatar Profiles SiteXpress
Similar Organizations
SyMap Medical
SyMap Medical is an innovative medical device company.
Current Employees Featured
Founder
Stock Details
Investors List
Remegen
Remegen investment in Post-IPO Equity - Biocytogen
Veken Technology
Veken Technology investment in Post-IPO Equity - Biocytogen
OrbiMed
OrbiMed investment in Series E - Biocytogen
CPE
CPE investment in Series E - Biocytogen
Octagon Capital Partners
Octagon Capital Partners investment in Series E - Biocytogen
Lake Bleu Capital
Lake Bleu Capital investment in Series E - Biocytogen
CMB International Capital Corporation
CMB International Capital Corporation investment in Series D - Biocytogen
China Life Healthcare Fund
China Life Healthcare Fund investment in Series D - Biocytogen
Cowin Capital
Cowin Capital investment in Series D - Biocytogen
3E Bioventures
3E Bioventures investment in Series D - Biocytogen
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-06-02 | Doma Biopharmaceutical | Biocytogen investment in Series A - Doma Biopharmaceutical | 950 M CNY |